# An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

> **NCT03439761** · PHASE1,PHASE2 · UNKNOWN · sponsor: **SciClone Pharmaceuticals** · enrollment: 125 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PT-112 Injection

## Key facts

- **NCT ID:** NCT03439761
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-07
- **Primary completion:** 2020-05
- **Final completion:** 2020-07
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2018-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03439761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03439761, "An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03439761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*